Related Experiment Video
Updated: Jul 1, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Identification of Key Molecular Pathways and Associated Genes as Targets to Overcome Radiotherapy Resistance Using a
Tianqi Zhang1, Qiao Zhang1, Xinwei He2
1Department of Population Health, New York University Grossman School of Medicine, New York, NY 10016, USA.
Abstract:
Recent mechanistic studies have indicated that combinations of radiotherapy (RT) plus immunotherapy (via CSF-1R inhibition) can serve as a strategy to overcome RT resistance and improve the survival of glioma mice. Given the high mortality rate for glioma, including low-grade glioma (LGG) patients, it is of critical importance to investigate the mechanism of the combination of RT and immunotherapy and further translate the mechanism from mouse studies to improve survival of RT-treated human glioma patients. Using the RNA-seq data from a glioma mouse study, 874 differentially expressed genes (DEGs) between the group of RT-treated mice at glioma recurrence and the group of mice with combination treatment (RT plus CSF-1R inhibition) were translated to the human genome to identify significant molecular pathways using the KEGG enrichment analysis. The enrichment analysis yields statistically significant signaling pathways, including the phosphoinositide 3-kinase (PI3K)/AKT pathway, Hippo pathway, and Notch pathway. Within each pathway, a candidate gene set was selected by Cox regression models as genetic biomarkers for resistance to RT and response to the combination of RT plus immunotherapies. Each Cox model is trained using a cohort of 295 RT-treated LGG patients from The Cancer Genome Atlas (TCGA) database and validated using a cohort of 127 RT-treated LGG patients from the Chinese Glioma Genome Atlas (CGGA) database. A four-DEG signature (ITGB8, COL9A3, TGFB2, JAG1) was identified from the significant genes within the three pathways and yielded the area under time-dependent ROC curve AUC = 0.86 for 5-year survival in the validation set, which indicates that the selected DEGs have strong prognostic value and are potential intervention targets for combination therapies. These findings may facilitate future trial designs for developing combination therapies for glioma patients.
Insights
Combining radiotherapy with immunotherapy shows promise for improving glioma survival. A new four-gene signature may predict treatment response and guide future combination therapies for patients.
Area of Science:
- Oncology
- Immunotherapy
- Radiotherapy
Background:
- Glioma, including low-grade glioma (LGG), has a high mortality rate.
- Radiotherapy (RT) combined with immunotherapy (CSF-1R inhibition) has shown potential in preclinical models.
- Translating these findings to human glioma patients is crucial for improving survival.
Purpose of the Study:
- To investigate the molecular mechanisms underlying the combination of RT and immunotherapy in glioma.
- To identify biomarkers for RT resistance and response to combination therapy.
- To translate findings from mouse models to human glioma patients.
Main Methods:
- RNA-sequencing data from a mouse glioma model were analyzed.
- Differentially expressed genes (DEGs) were identified and mapped to the human genome.
- KEGG enrichment analysis identified significant signaling pathways (PI3K/AKT, Hippo, Notch).
- Cox regression models selected candidate genes from these pathways.
- Gene signatures were trained and validated using TCGA and CGGA LGG patient cohorts.
Main Results:
- A four-DEG signature (ITGB8, COL9A3, TGFB2, JAG1) was identified.
- This signature demonstrated strong prognostic value, with an AUC of 0.86 for 5-year survival in the validation set.
- The identified genes are potential intervention targets for combination therapies.
Conclusions:
- The four-DEG signature has significant prognostic value for RT-treated LGG patients.
- These DEGs represent potential targets for developing novel combination therapies.
- Findings support future clinical trial designs for glioma treatment.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Treatment Resistant Cancers

